Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy.
2/5 보강
OpenAlex 토픽 ·
Lung Cancer Treatments and Mutations
Lung Cancer Diagnosis and Treatment
Lung Cancer Research Studies
[BACKGROUND] The LAURA study in unresectable stage III EGFR-mutated NSCLC without progression during/after chemoradiotherapy demonstrated significantly improved progression-free survival (PFS) with os
APA
Edurne Arriola, Ignacio Casarini, et al. (2026). Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy.. European journal of cancer (Oxford, England : 1990), 240, 116744. https://doi.org/10.1016/j.ejca.2026.116744
MLA
Edurne Arriola, et al.. "Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy.." European journal of cancer (Oxford, England : 1990), vol. 240, 2026, pp. 116744.
PMID
42019226
Abstract
[BACKGROUND] The LAURA study in unresectable stage III EGFR-mutated NSCLC without progression during/after chemoradiotherapy demonstrated significantly improved progression-free survival (PFS) with osimertinib versus placebo after definitive chemoradiotherapy. We report patient-reported outcomes (PROs) from LAURA.
[PATIENTS AND METHODS] Score changes from baseline (mixed model for repeated measures analysis) and time to confirmed deterioration in health-related quality of life (HRQoL), functioning and symptoms per EORTC QLQ-C30/LC13 questionnaires were analyzed. Tolerability was assessed using the PRO-CTCAE v1.0.
[RESULTS] Baseline EORTC scores were comparable between treatment arms. Risk of confirmed deterioration in key scales was generally not substantially different between arms (HR [95% CI], global health status/QoL 1.14 [0.74-1.78]; physical function 1.06 [0.65-1.71]; fatigue 1.23 [0.85-1.80]; appetite loss 1.00 [0.63-1.58]; dyspnea 1.30 [0.91-1.86]; coughing 1.17 [0.81-1.71]; pain in chest 1.46 [0.95-2.23]). Over 40 weeks, minimal changes from baseline were observed for key functioning/symptoms in both arms. PRO-CTCAE responses indicated similar tolerability of osimertinib versus placebo for symptom frequency and severity, except for loose/watery stools ("never"/"rarely" frequency vs. "never") and dry skin ("mild" severity vs. "none").
[CONCLUSIONS] PRO scores were maintained during osimertinib treatment of unresectable stage III EGFR-mutated NSCLC after definitive chemoradiotherapy. Together with significant PFS benefit and expected, manageable safety, the PRO data support osimertinib treatment in this setting.
[TRIAL REGISTRATION NUMBER] NCT03521154.
[PATIENTS AND METHODS] Score changes from baseline (mixed model for repeated measures analysis) and time to confirmed deterioration in health-related quality of life (HRQoL), functioning and symptoms per EORTC QLQ-C30/LC13 questionnaires were analyzed. Tolerability was assessed using the PRO-CTCAE v1.0.
[RESULTS] Baseline EORTC scores were comparable between treatment arms. Risk of confirmed deterioration in key scales was generally not substantially different between arms (HR [95% CI], global health status/QoL 1.14 [0.74-1.78]; physical function 1.06 [0.65-1.71]; fatigue 1.23 [0.85-1.80]; appetite loss 1.00 [0.63-1.58]; dyspnea 1.30 [0.91-1.86]; coughing 1.17 [0.81-1.71]; pain in chest 1.46 [0.95-2.23]). Over 40 weeks, minimal changes from baseline were observed for key functioning/symptoms in both arms. PRO-CTCAE responses indicated similar tolerability of osimertinib versus placebo for symptom frequency and severity, except for loose/watery stools ("never"/"rarely" frequency vs. "never") and dry skin ("mild" severity vs. "none").
[CONCLUSIONS] PRO scores were maintained during osimertinib treatment of unresectable stage III EGFR-mutated NSCLC after definitive chemoradiotherapy. Together with significant PFS benefit and expected, manageable safety, the PRO data support osimertinib treatment in this setting.
[TRIAL REGISTRATION NUMBER] NCT03521154.